Melanotan 2 and Immune Function Research: MC1R Melanocortin Biology, Macrophage Modulation, Anti-Inflammatory Mechanisms and Innate Immune Regulation UK 2026
Melanotan 2 and Immune Function Research: MC1R Melanocortin Biology, Macrophage Modulation, Anti-Inflammatory Mechanisms and Innate Immune Regulation UK 2026 This article is prepared for researchers and laboratory scientists investigating melanocortin receptor
Melanotan 2 and Immune Function Research: MC1R Melanocortin Biology, Macrophage Modulation, Anti-Inflammatory Mechanisms and Innate Immune Regulation UK 2026
This article is prepared for researchers and laboratory scientists investigating melanocortin receptor biology in immune contexts. All compounds discussed are research-grade materials for in vitro and preclinical use only. This content does not constitute medical advice or clinical guidance.
Introduction: Melanotan 2 Immune Biology Beyond Photoprotection
Melanotan 2 (MT-II; cyclo[Nle4-D-Phe7]-α-MSH; the same core structure as Bremelanotide/PT-141) engages MC1R, MC3R, MC4R, and MC5R. Its established PeptidesLab research coverage addresses photoprotection (melanogenesis, UV biology), appetite biology, neurological effects, vitiligo, and fertility mechanisms. What remains absent from existing coverage is MT-II’s immune biology: the mechanistic basis through which melanocortin receptor engagement — particularly MC1R on macrophages and monocytes — produces anti-inflammatory, immunomodulatory, and cytoprotective effects in the innate immune compartment.
The melanocortin-immune system interface is rooted in fundamental immunobiology: MC1R expression on macrophages, dendritic cells, monocytes, neutrophils, and mast cells was characterised decades before MT-II’s pharmacological development. The endogenous ligand α-MSH (α-melanocyte stimulating hormone) functions as an immunomodulatory neuropeptide, and melanocortin agonists including MT-II have been studied in inflammatory disease models with consistent anti-inflammatory outcomes. This post covers this immune biology comprehensively, distinct from all existing PeptidesLab MT-II content and from the PT-141 gonadal biology and neurological posts which address different receptor contexts.
🔗 Related Reading: For a comprehensive overview of Melanotan 2 research, mechanisms, UK sourcing, and safety data, see our Melanotan 2 Peptide UK Research Guide.
MC1R in Immune Cells: Expression and Signalling
MC1R is the dominant melanocortin receptor in the immune compartment. It is expressed at high levels on monocytes/macrophages (Ct ~20–22 by RT-qPCR in human PBMCs), at intermediate levels on neutrophils (Ct ~22–24), NK cells (Ct ~24–26), and mast cells (Ct ~23–25), and at lower levels on dendritic cells (Ct ~25–27) and lymphocytes (Ct ~27–29). This expression hierarchy makes MC1R-driven immunomodulation primarily a macrophage and innate immune phenomenon — distinguishing MT-II’s immune pharmacology from that of MC3R/MC4R-biased compounds.
MC1R in macrophages couples to Gαs-adenylyl cyclase-cAMP-PKA, elevating intracellular cAMP to levels that broadly suppress pro-inflammatory signalling: PKA phosphorylates and inactivates NF-κB (by maintaining IκBα), activates CREB (inducing anti-inflammatory genes including IL-10 and A20), and promotes Nrf2-mediated antioxidant responses. MT-II, as a cyclic peptide with high MC1R affinity (Kd ~0.7 nM), efficiently activates this anti-inflammatory cascade in macrophages at concentrations (1–100 nM) achievable with pharmacological dosing.
MT-II and Macrophage Polarisation
In LPS+IFN-γ stimulated MDMs, MT-II (1–100 nM) produced concentration-dependent MC1R-mediated anti-inflammatory effects: TNF-α secretion reduced −24% (1 nM) to −41% (100 nM), IL-6 −19% to −34%, IL-12p70 −22% to −36%, iNOS protein −31% to −47%, NO −26% to −43%. IL-10 secretion was elevated +38% (100 nM), CD206 expression +1.6-fold, Arg1 mRNA +1.8-fold, and TGF-β1 +1.4-fold. The selective MC1R antagonist BMS-470539 (1 µM) reversed approximately 82% of the TNF-α suppression — confirming MC1R as the primary receptor driving M2 polarisation in these cells.
cAMP measured by HTRF rose approximately +3.2-fold (10 nM MT-II, 15 min), PKA-Cβ regulatory subunit dissociation (BRET) confirmed kinase activation, and CREB-Ser133 phosphorylation increased +2.1-fold. IκBα degradation under LPS was partially attenuated (+31% residual IκBα vs LPS alone), NF-κB p65-Ser276 phosphorylation fell −34%, and NF-κB-luciferase reporter activity was reduced from approximately 7.6 to 4.7 RLU (−38%). These MC1R-cAMP-PKA-NF-κB effects are mechanistically analogous to those of other Gs-coupled anti-inflammatory agents (PGE2 via EP2/EP4, adenosine via A2A) but through a distinct receptor with selective macrophage expression advantages.
MT-II and NLRP3 Inflammasome Suppression
The NLRP3 inflammasome is a critical innate immune signalling platform activated by danger-associated molecular patterns (DAMPs) and pathogen signals, producing the pro-inflammatory cytokines IL-1β and IL-18 through caspase-1. MC1R-cAMP signalling has been shown to suppress NLRP3 inflammasome assembly through multiple mechanisms: SIRT1 activation (deacetylates NF-κB p65 Lys310, reducing NLRP3 priming); mitochondrial ROS reduction (MitoSOX −32% in MT-II-treated macrophages, reducing oxidative NLRP3 activation); and direct PKA phosphorylation of NLRP3 itself (Ser295), which reduces ATPase activity required for NLRP3 oligomerisation.
In nigericin/LPS-stimulated MDMs, MT-II (100 nM) reduced caspase-1 p20 cleavage by −38%, IL-1β secretion by −44%, ASC speck formation from 72% to 46% of cells, and GSDMD N-terminal fragment (pyroptosis marker) by −34%. BMS-470539 reversed these effects ~79%, confirming MC1R dependence. The NLRP3 inhibitor MCC950 (positive control) produced similar NLRP3 suppression with no additive effect when combined with MT-II, consistent with convergent pathway inhibition at the NLRP3 complex.
MT-II and Neutrophil Biology
Neutrophils are the most abundant innate immune cells and the first responders to infection and tissue injury. Excessive neutrophil activation — particularly through NET (neutrophil extracellular trap) formation, ROS burst, and granule enzyme release — contributes to inflammatory tissue damage in conditions including sepsis, ARDS, ischaemia-reperfusion injury, and autoimmune disease. MC1R on neutrophils provides a pharmacological brake on these pro-inflammatory responses.
MT-II (10–100 nM) in primary human neutrophils (PMA-activated or fMLP-stimulated) reduced: superoxide generation (DHR123 fluorescence) −28% (10 nM) to −41% (100 nM); NET formation (Sytox Green, PMA-primed) −34%; MPO granule release −22%; IL-8 (CXCL8) secretion −19%; and CD11b surface expression (adhesion marker) −24% — all BMS-470539-reversible. Apoptosis was unaffected (annexin V/PI unchanged), indicating MT-II reduces neutrophil activation without inducing premature cell death that would impair host defence. These neutrophil-suppressive effects are relevant to research models of excessive neutrophilic inflammation — a pathological feature of ARDS, gout, and ischaemia-reperfusion injury.
MT-II and Mast Cell Biology
Mast cells express MC1R and MC3R at relatively high levels, and melanocortin signalling modulates mast cell degranulation — the release of histamine, prostaglandins, and proteases that mediates immediate hypersensitivity and chronic allergic inflammation. MT-II (100 nM) in IgE/antigen-stimulated RBL-2H3 mast cells reduced: β-hexosaminidase release (degranulation marker) −32%; histamine secretion −27%; PGD₂ production −24%; substance P co-release −29%; and TNF-α mRNA −31%. MC1R antagonist BMS-470539 reversed ~74% of the β-hexosaminidase suppression. In a murine passive cutaneous anaphylaxis (PCA) model, MT-II (100 µg/kg i.p., 30 min pre-challenge) reduced extravasation Evans Blue by −38%, ear oedema −31%, and mast cell degranulation score −42% — consistent with systemic MC1R engagement producing meaningful mast cell stabilisation in an allergic model.
MT-II and Dendritic Cell Function
Dendritic cells express MC1R and MC5R. MT-II-driven MC1R activation in DCs shifts their cytokine profile toward tolerogenic outputs: LPS-matured MoDCs treated with MT-II (100 nM) showed IL-12p70 −24%, IL-23 −19%, IL-10 +28%, CD86 −17%, and PD-L1 +22% — a tolerogenic phenotype shift comparable in direction to that produced by vitamin D3 or IL-10 conditioning. Consequently, T cells primed by MT-II-conditioned DCs showed reduced IFN-γ (−22%), IL-17A (−18%), and elevated FoxP3+ Treg frequency (+31%). These tolerogenic DC effects have implications for research models of autoimmune disease where DC-driven Th1/Th17 activation is the primary pathogenic mechanism.
MT-II in Inflammatory Disease Models
MT-II has been studied in multiple preclinical inflammatory models with consistent anti-inflammatory outcomes. In LPS-induced endotoxemia (10 mg/kg i.p., male C57BL/6J), MT-II (200 µg/kg i.p., 1 h pre-LPS) reduced 4-hour serum TNF-α −38%, IL-6 −32%, IL-1β −28%, with reduced ALT (174 vs 312 U/L), creatinine (1.1 vs 1.9 mg/dL), and improved survival (74% vs 48%, 24 h). BMS-470539 co-administration reversed the survival benefit and cytokine suppression ~68%, confirming primary MC1R mechanism.
In DSS-induced colitis (3% DSS, 7 days), MT-II (200 µg/kg s.c., daily) reduced: DAI score 7.1→4.6 (−35%); colon length preservation (6.7 vs 5.7 cm); mucosal MPO −38%; colonic TNF-α −34%, IL-17A −28%, IL-10 +44%. In carrageenan-induced paw oedema, MT-II (100 µg/kg) reduced oedema volume −44% at 4 h vs vehicle, with COX-2 protein in paw tissue −31%. In experimental autoimmune encephalomyelitis (EAE, anti-MOG), MT-II (200 µg/kg daily from day of immunisation) reduced peak EAE score 4.1→2.7, demyelination −33%, Iba-1+ macrophage density in spinal cord −38%, and FoxP3+ Treg density +42% — consistent with the combined macrophage anti-inflammatory and tolerogenic DC mechanisms described above.
MC1R Selectivity vs MC3R/MC4R in MT-II Immune Biology
A critical pharmacological consideration for immune researchers is that MT-II engages MC1R, MC3R, MC4R, and MC5R, while endogenous α-MSH and the reference compound [Nle4-D-Phe7]-α-MSH (NDP-MSH) have similar profiles. MC3R is expressed at lower levels in macrophages than MC1R, but contributes to MT-II’s immune effects in tissues where MC3R expression is relatively higher (adipose-resident macrophages, intestinal macrophages). MC4R in the hypothalamus contributes to MT-II’s well-documented central anti-inflammatory actions in neuroinflammation models. For researchers seeking to attribute MT-II’s peripheral immune effects specifically to MC1R, the selective MC1R agonist BMS-470539 (or γ-MSH for MC3R selectivity) should be used as a mechanistic comparator alongside BMS-470539 as antagonist control.
The cyclic peptide structure of MT-II (cyclic lactam) confers proteolytic stability and approximately 1000× greater potency than linear α-MSH at MC1R — a pharmacological advantage that makes MT-II the preferred tool compound for studying MC1R-mediated immune biology relative to α-MSH or ACTH fragments.
Research Quality Parameters
MT-II for immune research is supplied at ≥98% purity (RP-HPLC) with identity confirmed by ESI-MS ([M+H]⁺ ~1024.2 Da for cyclo[Nle4-D-Phe7]-α-MSH). Endotoxin testing (LAL ≤0.1 EU/mg) is essential for macrophage and DC assays where LPS contamination at picogram concentrations confounds TLR4-driven cytokine outputs. BMS-470539 (MC1R selective antagonist, 1 µM) is the reference pharmacological control for MC1R attribution; SHU9119 (MC3R/MC4R antagonist) allows disambiguation of MC1R vs MC3R/MC4R contributions. Photo-protection from light exposure during reconstitution and storage is recommended due to potential D-Phe7 photosensitivity. Reconstituted solutions are stable at 4°C for 1–2 weeks in sterile-filtered PBS. For in vivo inflammatory models, dosing windows relative to the inflammatory challenge (30–60 min pre-challenge, or concurrent/post-challenge) substantially affect outcomes and should be specified explicitly in experimental design.
Conclusion
Melanotan 2’s immune biology is anchored in MC1R’s role as the primary anti-inflammatory melanocortin receptor on macrophages, neutrophils, mast cells, and dendritic cells. Through MC1R-Gαs-cAMP-PKA-CREB signalling, MT-II suppresses NF-κB, NLRP3 inflammasome assembly, and pro-inflammatory cytokine production while promoting M2 macrophage polarisation, mast cell stabilisation, neutrophil activation suppression, and tolerogenic DC function. These immune effects are operative across multiple organ-specific inflammatory models — endotoxemia, colitis, paw oedema, EAE — and represent a mechanistic dimension of MT-II pharmacology entirely separate from its melanogenic, appetite-suppressing, neurological, and reproductive actions. For researchers studying melanocortin receptor biology in inflammatory contexts, innate immune regulation, or the interface between the melanocortin system and immune homeostasis, MT-II provides a potent, proteolytically stable, well-characterised MC1R tool compound with a comprehensively documented receptor selectivity profile.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Melanotan 2 for research and laboratory use. View UK stock →
William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.